Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor

Stefano De Santis; Andrea Pace; Loredana Bove; Francesco Cognetti; Francesca Properzi; Marco Fiore; Viviana Triaca; Antonella Savarese; Maria Domenica Simone; Bruno Jandolo; Luigi Manzione; Luigi Aloe

Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor

Stefano De Santis, Andrea Pace, Loredana Bove, Francesco Cognetti, Francesca Properzi, Marco Fiore, Viviana Triaca, Antonella Savarese, Maria Domenica Simone, Bruno Jandolo, Luigi Manzione, Luigi Aloe

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of our study was to explore whether nerve growth factor (NGF) plays any role in the development of peripheral neuropathy induced by anticancer treatment. We measured the circulating NGF levels in 23 cancer patients before and after chemotherapy. We evaluated whether the development of peripheral neurotoxicity was associated with changes in basal NGF concentrations in patients studied with a comprehensive neurological and neurophysiological examination. The results of these studies showed that the circulating levels of NGF, which are about 20 pg/ml in plasma of controls, decrease during chemotherapy and in some cases completely disappeared after prolonged treatment with antitumor agents. The decrease in NGF levels seems to be correlated with the severity of neurotoxicity. These results clearly suggest that NGF might become a useful agent to prevent neuropathies induced by antineoplastic drugs and restore peripheral nerve dysfunction induced by these pharmacological compounds.

Original language	English
Pages (from-to)	90-95
Number of pages	6
Journal	Clinical Cancer Research
Volume	6
Issue number	1
Publication status	Published - Jan 2000

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

Fingerprint Dive into the research topics of 'Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor'. Together they form a unique fingerprint.

Cite this

Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. / De Santis, Stefano; Pace, Andrea; Bove, Loredana; Cognetti, Francesco; Properzi, Francesca; Fiore, Marco; Triaca, Viviana; Savarese, Antonella; Simone, Maria Domenica; Jandolo, Bruno; Manzione, Luigi; Aloe, Luigi.

In: Clinical Cancer Research, Vol. 6, No. 1, 01.2000, p. 90-95.

Research output: Contribution to journal › Article › peer-review

De Santis, Stefano ; Pace, Andrea ; Bove, Loredana ; Cognetti, Francesco ; Properzi, Francesca ; Fiore, Marco ; Triaca, Viviana ; Savarese, Antonella ; Simone, Maria Domenica ; Jandolo, Bruno ; Manzione, Luigi ; Aloe, Luigi. / Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 1. pp. 90-95.

@article{c2830807430549b6a529b7934b9eed8e,

title = "Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor",

abstract = "The aim of our study was to explore whether nerve growth factor (NGF) plays any role in the development of peripheral neuropathy induced by anticancer treatment. We measured the circulating NGF levels in 23 cancer patients before and after chemotherapy. We evaluated whether the development of peripheral neurotoxicity was associated with changes in basal NGF concentrations in patients studied with a comprehensive neurological and neurophysiological examination. The results of these studies showed that the circulating levels of NGF, which are about 20 pg/ml in plasma of controls, decrease during chemotherapy and in some cases completely disappeared after prolonged treatment with antitumor agents. The decrease in NGF levels seems to be correlated with the severity of neurotoxicity. These results clearly suggest that NGF might become a useful agent to prevent neuropathies induced by antineoplastic drugs and restore peripheral nerve dysfunction induced by these pharmacological compounds.",

author = "{De Santis}, Stefano and Andrea Pace and Loredana Bove and Francesco Cognetti and Francesca Properzi and Marco Fiore and Viviana Triaca and Antonella Savarese and Simone, {Maria Domenica} and Bruno Jandolo and Luigi Manzione and Luigi Aloe",

year = "2000",

month = jan,

language = "English",

volume = "6",

pages = "90--95",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

TY - JOUR

T1 - Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor

AU - De Santis, Stefano

AU - Pace, Andrea

AU - Bove, Loredana

AU - Cognetti, Francesco

AU - Properzi, Francesca

AU - Fiore, Marco

AU - Triaca, Viviana

AU - Savarese, Antonella

AU - Simone, Maria Domenica

AU - Jandolo, Bruno

AU - Manzione, Luigi

AU - Aloe, Luigi

PY - 2000/1

Y1 - 2000/1

N2 - The aim of our study was to explore whether nerve growth factor (NGF) plays any role in the development of peripheral neuropathy induced by anticancer treatment. We measured the circulating NGF levels in 23 cancer patients before and after chemotherapy. We evaluated whether the development of peripheral neurotoxicity was associated with changes in basal NGF concentrations in patients studied with a comprehensive neurological and neurophysiological examination. The results of these studies showed that the circulating levels of NGF, which are about 20 pg/ml in plasma of controls, decrease during chemotherapy and in some cases completely disappeared after prolonged treatment with antitumor agents. The decrease in NGF levels seems to be correlated with the severity of neurotoxicity. These results clearly suggest that NGF might become a useful agent to prevent neuropathies induced by antineoplastic drugs and restore peripheral nerve dysfunction induced by these pharmacological compounds.

AB - The aim of our study was to explore whether nerve growth factor (NGF) plays any role in the development of peripheral neuropathy induced by anticancer treatment. We measured the circulating NGF levels in 23 cancer patients before and after chemotherapy. We evaluated whether the development of peripheral neurotoxicity was associated with changes in basal NGF concentrations in patients studied with a comprehensive neurological and neurophysiological examination. The results of these studies showed that the circulating levels of NGF, which are about 20 pg/ml in plasma of controls, decrease during chemotherapy and in some cases completely disappeared after prolonged treatment with antitumor agents. The decrease in NGF levels seems to be correlated with the severity of neurotoxicity. These results clearly suggest that NGF might become a useful agent to prevent neuropathies induced by antineoplastic drugs and restore peripheral nerve dysfunction induced by these pharmacological compounds.

UR - http://www.scopus.com/inward/record.url?scp=17044460959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044460959&partnerID=8YFLogxK

M3 - Article

C2 - 10656436

AN - SCOPUS:17044460959

VL - 6

SP - 90

EP - 95

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -